0.590
0.01 (1.22%)
| Penutupan Terdahulu | 0.583 |
| Buka | 0.580 |
| Jumlah Dagangan | 2,876,701 |
| Purata Dagangan (3B) | 18,943,206 |
| Modal Pasaran | 81,083,136 |
| Harga / Buku (P/B) | 16.23 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| Margin Operasi (TTM) | -333.90% |
| EPS Cair (TTM) | -2.78 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -36.90% |
| Nisbah Semasa (MRQ) | 1.03 |
| Aliran Tunai Operasi (OCF TTM) | -12.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -7.34 M |
| Pulangan Atas Aset (ROA TTM) | -105.59% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | PLUS THERAPEUTICS, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.63 |
|
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.02% |
| % Dimiliki oleh Institusi | 2.50% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Dagco, Inc. | 30 Sep 2025 | 25,882 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 19.00 (Ascendiant Capital, 3,120.34%) | Beli |
| Median | 5.00 (747.46%) | |
| Rendah | 2.00 (HC Wainwright & Co., 238.98%) | Beli |
| Purata | 8.67 (1,369.49%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 0.543 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 01 Dec 2025 | 5.00 (747.46%) | Beli | 0.580 |
| 20 Nov 2025 | 5.00 (747.46%) | Beli | 0.490 | |
| Ascendiant Capital | 21 Nov 2025 | 19.00 (3,120.34%) | Beli | 0.530 |
| 06 Oct 2025 | 21.00 (3,459.32%) | Beli | 0.890 | |
| HC Wainwright & Co. | 03 Nov 2025 | 2.00 (238.98%) | Beli | 0.520 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |